Sex differences in the efficacy and safety of SARS-CoV-2 vaccination in residents of long-term care facilities : insights from the GeroCovid Vax study
© 2023. The Author(s)..
Despite the reported sex-related variations in the immune response to vaccination, whether the effects of SARS-CoV-2 vaccination differ by sex is still under debate, especially considering old vulnerable individuals, such as long-term care facilities (LTCFs) residents. This study aimed to evaluate COVID-19 infections, adverse events, and humoral response after vaccination in a sample of LTCF residents. A total of 3259 LTCF residents (71% females; mean age: 83.4 ± 9.2 years) were enrolled in the Italian-based multicenter GeroCovid Vax study. We recorded the adverse effects occurring during the 7 days after vaccine doses and COVID-19 cases over 12 months post-vaccination. In a subsample of 524 residents (69% females), pre- and post-vaccination SARS-CoV-2 trimeric S immunoglobulin G (Anti-S-IgG) were measured through chemiluminescent assays at different time points. Only 12.1% of vaccinated residents got COVID-19 during the follow-up, without any sex differences. Female residents were more likely to have local adverse effects after the first dose (13.3% vs. 10.2%, p = 0.018). No other sex differences in systemic adverse effects and for the following doses were recorded, as well as in anti-S-IgG titer over time. Among the factors modifying the 12-month anti-S-IgG titers, mobility limitations and depressive disorder were more likely to be associated with higher and lower levels in the antibody response, respectively; a significantly lower antibody titer was observed in males with cardiovascular diseases and in females with diabetes or cognitive disorders. The study suggests that, among LTCF residents, SARS-CoV-2 vaccination was effective regardless of sex, yet sex-specific comorbidities influenced the antibody response. Local adverse reactions were more common in females.
| Errataetall: |
CommentIn: Intern Emerg Med. 2023 Nov;18(8):2163-2164. - PMID 37658950 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Internal and emergency medicine - 18(2023), 5 vom: 29. Aug., Seite 1337-1347 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Trevisan, Caterina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 10.08.2023 Date Revised 20.11.2023 published: Print-Electronic CommentIn: Intern Emerg Med. 2023 Nov;18(8):2163-2164. - PMID 37658950 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11739-023-03283-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356240568 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356240568 | ||
| 003 | DE-627 | ||
| 005 | 20231226070039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11739-023-03283-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356240568 | ||
| 035 | |a (NLM)37120663 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trevisan, Caterina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sex differences in the efficacy and safety of SARS-CoV-2 vaccination in residents of long-term care facilities |b insights from the GeroCovid Vax study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.08.2023 | ||
| 500 | |a Date Revised 20.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Intern Emerg Med. 2023 Nov;18(8):2163-2164. - PMID 37658950 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Despite the reported sex-related variations in the immune response to vaccination, whether the effects of SARS-CoV-2 vaccination differ by sex is still under debate, especially considering old vulnerable individuals, such as long-term care facilities (LTCFs) residents. This study aimed to evaluate COVID-19 infections, adverse events, and humoral response after vaccination in a sample of LTCF residents. A total of 3259 LTCF residents (71% females; mean age: 83.4 ± 9.2 years) were enrolled in the Italian-based multicenter GeroCovid Vax study. We recorded the adverse effects occurring during the 7 days after vaccine doses and COVID-19 cases over 12 months post-vaccination. In a subsample of 524 residents (69% females), pre- and post-vaccination SARS-CoV-2 trimeric S immunoglobulin G (Anti-S-IgG) were measured through chemiluminescent assays at different time points. Only 12.1% of vaccinated residents got COVID-19 during the follow-up, without any sex differences. Female residents were more likely to have local adverse effects after the first dose (13.3% vs. 10.2%, p = 0.018). No other sex differences in systemic adverse effects and for the following doses were recorded, as well as in anti-S-IgG titer over time. Among the factors modifying the 12-month anti-S-IgG titers, mobility limitations and depressive disorder were more likely to be associated with higher and lower levels in the antibody response, respectively; a significantly lower antibody titer was observed in males with cardiovascular diseases and in females with diabetes or cognitive disorders. The study suggests that, among LTCF residents, SARS-CoV-2 vaccination was effective regardless of sex, yet sex-specific comorbidities influenced the antibody response. Local adverse reactions were more common in females | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Efficacy | |
| 650 | 4 | |a Nursing homes | |
| 650 | 4 | |a SARS-CoV-2 vaccines | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a Sex differences | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Raparelli, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Malara, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Abbatecola, Angela Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Noale, Marianna |e verfasserin |4 aut | |
| 700 | 1 | |a Palmieri, Annapina |e verfasserin |4 aut | |
| 700 | 1 | |a Fedele, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Di Lonardo, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, Pasqualina |e verfasserin |4 aut | |
| 700 | 1 | |a Schiavoni, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Stefanelli, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Volpato, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Antonelli Incalzi, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Onder, Graziano |e verfasserin |4 aut | |
| 700 | 0 | |a GeroCovid Vax working group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal and emergency medicine |d 2006 |g 18(2023), 5 vom: 29. Aug., Seite 1337-1347 |w (DE-627)NLM165086432 |x 1828-0447 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:5 |g day:29 |g month:08 |g pages:1337-1347 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11739-023-03283-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 5 |b 29 |c 08 |h 1337-1347 | ||